Table 1.
The clinical summary of included studies for sarcoidosis.
| Author | Year | Country | Criterial | Diseased Region | Method | Sarcoidosis | Control | Design | Cut-Off | TP | FP | FN | TN | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Age | Gender (M/F) | sACE | Unit | Control | Age | Gender (M/F) | sACE | Unit | ||||||||||||
| Lieberman et al. [26] | 1975 | US | Histology | NA | Spectrophotometry | 17 | NA | NA | 13.65 ± 2.26 | U/mL | 296 | NA | NA | NA | U/mL | NA | 11.6 | 15 | 9 | 2 | 287 |
| Silverstein et al. [27] | 1976 | US | NA | NA | Spectrophotometry | 58 | 48.3 ± 4.8 | NA | 48.3 + 4.8 | nmol/min/mL | 256 | NA | NA | NA | nmol/min/mL | NA | 30.48 | 20 | 15 | 38 | 241 |
| Studdy et al. [28] | 1978 | UK | Histology | NA | Spectrophotometry | 90 | NA | NA | 58 ± 24 | nmol/min/mL | 194 | NA | NA | NA | nmol/min/mL | NA | 52 | 45 | 14 | 45 | 180 |
| Turton et al. [29] | 1979 | UK | Histology | NA | Spectrophotometry | 72 | 37(19–67) | 31/41 | 35.6 ± 14.4 | U/mL | 87 | NA | NA | NA | U/mL | NA | 41 | 21 | 3 | 51 | 84 |
| Lieberman et al. [30] | 1979 | US | NA | NA | Spectrophotometry | 391 | 39.6 ± 10 | NA | NA | U/mL | 1150 | NA | NA | NA | U/mL | NA | 35 | 226 | 30 | 165 | 1120 |
| Rohrbach et al. [31] | 1979 | US | Histology | NA | Radiochemistry | 42 | 44.8 | 22/20 | 71.9 ± 19.2 | U/mL | 60 | NA | NA | 40.2 ± 8.6 | U/mL | R | 57 | 33 | 3 | 9 | 57 |
| Rohatgi et al. [32] | 1980 | US | Histology | NA | Radiochemistry | 55 | 17–69 | NA | NA | mU/mL | 122 | NA | NA | NA | mU/mL | NA | 137.5 | 35 | 7 | 20 | 115 |
| Ryder et al. [33] | 1981 | US | Clinical findings and/or histology | NA | Spectrophotometry | 40 | NA | NA | 44 ± 8 | kU/L | 60 | NA | NA | NA | kU/L | P | 35 | 36 | 5 | 4 | 55 |
| Ainslie et al. [35] | 1985 | South Africa | Histology | NA | Spectrophotometry | 303 | NA | NA | NA | nmol/min/mL | 210 | NA | NA | NA | nmol/min/mL | R | 54 | 176 | 34 | 127 | 176 |
| Baarsma et al. [36] | 1987 | Netherlands | Clinical and biochemical findings | Ocular sarcoidosis | Spectrophotometry | 12 | NA | NA | NA | U/L | 209 | NA | NA | NA | U/L | NA | 50 | 10 | 10 | 2 | 199 |
| Bunting et al. [37] | 1987 | Canada | Clinical findings or histology | NA | Fluorimetry | 120 | NA | NA | NA | U/L | 74 | NA | NA | NA | U/L | NA | 50 | 76 | 5 | 44 | 69 |
| Power et al. [38] | 1995 | US | Histology | Ocular sarcoidosis | Spectrophotometry | 22 | 35 (22–64) | 10/12 | NA | U/L | 70 | 39 (17–58) | 29/41 | NA | U/L | R | 52 | 16 | 12 | 6 | 58 |
| Khan et al. [39] | 1998 | Pakistan | Clinical findings and/or histology | NA | Spectrophotometry | 51 | NA | NA | 104.44 | IU/L | 62 | NA | NA | NA | IU/L | R | 52 | 44 | 24 | 7 | 38 |
| Bons et al. [40] | 2007 | Netherlands | WASOG | NA | Spectrophotometry | 35 | 45.67 ± 8.8 | 18/17 | 22.0 (16.0–24.0) | U/L | 35 | 47.37 ± 9.8 | 16/19 | 13.5 (12.0–17.8) | U/L | p | 16.5 | 25 | 10 | 10 | 25 |
| Kawaguchi et al. [41] | 2007 | Japan | Histology | Ocular sarcoidosis | NA | 60 | NA | NA | NA | NA | 86 | NA | NA | NA | NA | R | NA | 35 | 4 | 25 | 82 |
| Smet et al. [42] | 2010 | Belgium | Histology | NA | Spectrophotometry | 36 | NA | 21/15 | 48 (39–80) | U/L | 117 | NA | 65/52 | 27 (19–40) | U/L | R | 34 | 30 | 39 | 6 | 78 |
| Gungor et al. [43] | 2015 | Turkey | Histology | NA | Spectrophotometry | 48 | 44.29 ± 10.90 | 9/39 | 49.50 ± 41.04 | U/L | 20 | 38.05 ± 8.36 | 10/10 | 25.44 ± 13.38 | U/L | P | NA | 35 | 8 | 13 | 12 |
| Gundlach et al. [17] | 2016 | Germany | IWOS | Ocular sarcoidosis | Spectrophotometry | 41 | NA | NA | NA | U/mL | 220 | NA | NA | NA | U/mL | R | 82 | 9 | 1 | 32 | 219 |
| Hakan et al. [44] | 2017 | Netherlands | IWOS | Ocular sarcoidosis | Spectrophotometry | 37 | NA | NA | NA | U/L | 212 | NA | NA | NA | U/L | R | 51 | 20 | 64 | 17 | 148 |
| Uysal et al. [45] | 2018 | Turkey | WASOG | NA | ELISA | 59 | NA | NA | NA | mg/mL | 25 | 46.1 ± 8.4 | 12/13 | NA | mg/mL | NA | 5.37 | 52 | 7 | 2 | 23 |
| Niederer et al. [46] | 2018 | UK | IWOS | NA | NA | 110 | NA | NA | 32 (21–47) | NA | 925 | NA | NA | NA | NA | P | 52 | 85 | 111 | 25 | 814 |
| Csongrádi et al. [47] | 2018 | Hungary | Histology | NA | Fluorimetry | 40 | 39.0 ± 11.0 | 22/18 | NA | U/L | 11 | 54.0 ± 15.2 | 8/3 | 9.12 ± 2.07 | U/L | P | 21.4 | 9 | 0 | 31 | 11 |
| Eurelings et al. [48] | 2019 | Netherlands | ATS/ERS/WASOG | NA | Spectrophotometry | 101 | 43 (35–52) | 50/51 | 77 (44–109) | U/mL | 88 | 44 (31–57) | 36/52 | 51(31–69) | U/mL | R | 68 | 63 | 21 | 38 | 67 |
| Baba et al. [49] | 2019 | Japan | JSSOG 2015 | NA | Spectrophotometry | 79 | 65.0 (55.0–71.0) | 27/52 | 20.3 (16.0–24.4) | IU/L | 299 | NA | NA | 15.4 (12.8–18.5) | IU/L | R | 17.7 | 53 | 93 | 26 | 206 |
| Ishihara et al. [50] | 2020 | Japan | Clinical findings and/or histology | Ocular sarcoidosis | Spectrophotometry | 52 | 58.8 ± 15.2 | 13/39 | 26.4 ± 9.18 | U/L | 74 | 49.6 ± 16.5 | 40/34 | 13.5 ± 3.83 | U/L | R | NA | 23 | 0 | 29 | 74 |
| Enyedi et al. [51] | 2020 | Hungary | Histology | NA | Fluorimetry | 69 | 40.9 (±12.3) | 30/39 | 11.89 (10.5–13.7) | U/L | 168 | NA | NA | NA | U/L | P | NA | 17 | 0 | 52 | 168 |
| Komoriyama et al. [52] | 2020 | Japan | Histology | NA | Spectrophotometry | 37 | 57 ± 12 | 7/30 | 15.5 ± 7.9 | IU/L | 57 | 61 ± 9 | 12/45 | 12.4 ± 6.9 | IU/L | R | 13.5 | 21 | 26 | 16 | 31 |
| Suzukiet al. [53] | 2021 | Japan | Histology | Ocular sarcoidosis | ELISA | 77 | 54.6 ± 14.8 | NA | NA | U/L | 79 | 43.2 ± 17.8 | NA | NA | U/L | R | 12.7 | 29 | 2 | 48 | 77 |
| Papasavvas et al. [54] | 2021 | Switzerland | IWOS | Ocular sarcoidosis | Spectrophotometry | 37 | 54.52 ± 23.74 | NA | 49.17 ± 29 | U/L | 30 | 41 ± 11.3 | NA | 27.4 ± 15.34 | U/L | R | NA | 10 | 1 | 27 | 29 |
| Sunaga et al. [55] | 2022 | Japan | Histology | NA | Spectrophotometry | 112 | 61(14–86) | 36/78 | 20.2 (0–56.4) | IU/L | 62 | NA | NA | NA | IU/L | R | 21.4 | 46 | 0 | 66 | 62 |
| Wang et al. [56] | 2022 | China | Histology | NA | Spectrophotometry | 70 | 55.94 ± 11:83 | 14/56 | 56:61 ± 30.80 | U/L | 14 | 55.25 ± 16:70 | 8/6 | 28:07 ± 14.11 | U/L | P | 44 | 43 | 1 | 27 | 13 |
FN, false negative; FP, false positive; TN, true negative; TP, true positive; NA: not available; P: prospective; R: retrospective WASOG: World Association of Sarcoidosis and Other Granulomatous Disorders; ATS: the American Thoracic Society; ERS: the European Respiratory Society; IWOS: International Workshop on Ocular Sarcoidosis; sACE: serum angiotensin-converting enzyme.